Christopher T. Walsh

Department of Biological Chemistry & Molecular Pharmacology
Harvard Medical School
Armenise Building, Room 616
220 Longwood Ave., Boston, MA 02115

tel: (617) 432-1715; fax: (617) 432-0438
Email: Christopher_walsh@hms.harvard.edu

Research Interests:

The broad area of interest to this laboratory is the molecular basis of biological catalysis with focus on the structure and function of enzymes. Three of the several ongoing projects illustrate our approaches.

We are investigating enzymes in bacterial cell wall biosynthesis, either to analyze the mechanism of action of known antibiotics (vancomycin, fosfomycin, cycloserine) or to identify novel targets for drug design. For example, we have cloned, sequenced, expressed, overproduced, and purified to homogeneity eight enzymes in the peptidoglycan biosynthetic pathway and studied their mechanism of catalysis and inhibition. We have also studied the molecular mechanism of development of clinical resistance to vancomycin and identified the function of five genes necessary and sufficient for resistance, overproduced and purified the proteins and elucidated their catalytic function to decode the structural changes that produce a vancomycin-resistant peptidoglycan and thereby dangerously pathogenic bacteria.

We have initiated research in collaboration with Roberto Kolter's group into the biosynthesis of thiazole- and oxazole-containing peptide antibiotics with specific focus on the E. coli 43 residue peptide microcin B17. We have purified the three enzyme complex that converts prepromicrocin to mature microcin that has undergone modification of 6 gly, 4 cys, and 4 ser residues to yield 4 thiazole and 4 oxazole residues with gain of antibiotic activity. We are studying structure/function issues to see if we can get enzymatic synthesis of microcin analogs that still inactivate DNA gyrase.

During the synthesis of fatty acids, of polyketide natural products (with structures that include erythromycin, amphotericin, rapamycin, and adriamycin), and non-ribosomal peptides (such as cyclosporin, vancomycin), a common post translational modification converts the apo-form of acyl carrier protein (ACP) domains to the holoforms by enzyme-catalyzed phosphopantetheinylation of a conserved serine residue. This introduces the sulfhydryl of the P-pantetheinyl moiety (from cosubstrate CoASH) covalently into the protein and the SH group serves to carry acyl groups in the several transfers in fatty acid, polyketide, and polypeptide antibiotic assembly. We are studying the specificity and mechanism of the enzymes that carry out this phosphopantetheinyl group transfer from CoASH to serine side chains of ACP domains in both polyketide and nonribosomal peptide synthases.

Selected Publications:

Christopher Walsh (2000). Molecular Mechanisms that Confer Antibacterial Drug resistance. Nature 406:775-781.

Christopher Walsh (2001). Enabling the Chemistry of Life. Nature, 409:226-231.

John Trauger, Rahul Kohli, Henning Mootz, Mohamed Marahiel, Christopher Walsh (2000). Peptide cyclization catalysed by the thioesterase domain of tyrocidine synthetase. Nature 407, 215-218.

Page created and maintained by Xaq Pitkow